Yes, the 46% over 5% FEV increase also includes the 30% that saw a 10% increase. It must be noted though that the study was split into three groups - all had the same dosage of kalydeco (vx-770) but the VX-809 dosage was varied between the three groups (200mg,400mg,600mg). They would nt say in the conference call but I was wondering whether their was a correlation between the FEV increase and the dosage - hence not everyone in the study achieved the same levels of increase (maybe this is just wishful thinking).
Anyway, Vertex have seen enough that they are pushing ahead with the next stage and are not going to wait for the results of VX-661 (which it had been suggested was the better potentiator).
Anyway, Vertex have seen enough that they are pushing ahead with the next stage and are not going to wait for the results of VX-661 (which it had been suggested was the better potentiator).